Ocugen, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Shankar Musunuri
- Full Time Employees
- 116
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 263 Great Valley Parkway Malvern PA United States of America 19355
- IPO Date
- Dec 3, 2014
- CIK
- 0001372299
- Website
- ocugen.com
- Similar Companies
- Business
- Ocugen, Inc. is a clinical-stage biotechnology firm dedicated to advancing novel gene and cell therapies, alongside vaccines, to address a range of significant health challenges. The company's innovative pipeline emphasizes its modifier gene therapy platform, which employs a gene-agnostic strategy designed to potentially treat numerous retinal diseases with a single therapeutic agent. Leading their ocular initiatives, OCU400 is currently undergoing Phase 3 clinical trials for inherited retinal dystrophies like Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA), with plans for Biologics License Application (BLA) and Marketing Authorization Application (MAA) submissions anticipated by mid-2026. Another key program, OCU410ST, a modifier gene therapy for Stargardt disease, recently commenced its Phase 2/3 pivotal confirmatory trial, targeting a BLA filing in 2027. Additionally, OCU410, aimed at geographic atrophy secondary to dry age-related macular degeneration (dAMD), completed Phase 2 dosing and is slated for Phase 3 in 2026. Beyond gene therapies, Ocugen is progressing OCU200, a recombinant fusion protein, now in Phase 1 for conditions such as diabetic macular edema (DME), diabetic retinopathy, and wet AMD. The company is also involved in vaccine development, including an inhaled COVID-19 vaccine (OCU500) within a NIAID-funded trial, and has a cell therapy, NeoCart, in Phase 3 for knee cartilage repair. Ocugen engages in strategic alliances to propel its development and commercialization efforts. It maintains a collaboration with CanSino Biologics Inc. for the co-development and manufacturing of its gene therapy candidates, which includes commercialization rights in Greater China. The company also recently entered a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400, providing upfront and milestone payments, as well as royalties. Furthermore, Ocugen continues its partnership with Bharat Biotech for the commercialization of COVAXIN in the United States. The company is headquartered in Malvern, Pennsylvania.
Company News
Ocugen to Participate in Upcoming Scientific Conferences
Ocugen to Participate in Upcoming October Investor and Industry Conferences
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen to Participate in Upcoming September Investor and Industry Conferences
Brokerages Set Ocugen, Inc. (NASDAQ:OCGN) Price Target at $9.50
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Ocugen Q2 Earnings Call Highlights
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
Ocugen to Participate in Upcoming August Investor Conferences
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa